Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to $3.5 million.

  • Dianthus Therapeutics' Non Operating Income fell 2545.49% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year decrease of 1169.37%. This contributed to the annual value of $16.9 million for FY2024, which is 26577.18% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Non Operating Income stood at $3.5 million, which was down 2545.49% from $3.3 million recorded in Q2 2025.
  • Dianthus Therapeutics' Non Operating Income's 5-year high stood at $4.7 million during Q3 2024, with a 5-year trough of $470000.0 in Q3 2022.
  • Moreover, its 4-year median value for Non Operating Income was $3.3 million (2025), whereas its average is $2.5 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Non Operating Income soared by 62279.87% in 2024 and then crashed by 2825.76% in 2025.
  • Dianthus Therapeutics' Non Operating Income (Quarter) stood at $577000.0 in 2022, then soared by 314.73% to $2.4 million in 2023, then soared by 45.26% to $3.5 million in 2024, then rose by 1.35% to $3.5 million in 2025.
  • Its Non Operating Income stands at $3.5 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.7 million for Q1 2025.